Sertraline versus other antidepressive agents for depression

Cipriani, Andrea; Ferla, T. La; Furukawa, Toshi A; Signoretti, Alessandra; Nakagawa, Atsuo; Churchill, Rachel; McGuire, Hugh; Barbui, Corrado

doi:10.1002/14651858.cd006117.pub2

Cited by 87 publications

(45 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sertraline was selected as the SSRI in this study because it is among the more selective 5- HT re-uptake inhibitors, has an excellent profile for safety and effectiveness in the treatment of major depression in the context of comorbid illness (33) has linear kinetics and minimal age effect on clearance (34). The primary results of depression response to treatment have been previously reported (13).…”

Section: Methodsmentioning

confidence: 99%

Cognitive Improvement Following Treatment in Late-Life Depression: Relationship to Vascular Risk and Age of Onset

Deanna

D’Angelo

Pieper

et al. 2012

The American Journal of Geriatric Psychiatry

View full text Add to dashboard Cite

Objectives To test the hypothesis that the degree vascular burden and/or age of onset may influence the degree to which cognition can improve during the course of treatment in late life depression. Design Measurement of cognition both prior to and following 12-weeks of treatment with Sertraline. Setting University Medical Centers (Washington University and Duke University) Participants 166 individuals with late life depression. Intervention Sertraline treatment. Measurements The cognitive tasks were grouped into five domains (language, processing speed, working memory, episodic memory, and executive function). We measured vascular risk using the Framingham Stroke Risk Profile measure. We measured T2 based white matter hyperintensities using the Fazekas criteria. Results Both episodic memory and executive function demonstrated significant improvement among adults with late life depression during treatment with sertraline. Importantly, older age, higher vascular risk scores, and lower baseline Mini-Mental state exam scores predicted less change in working memory. Further, older age, later age of onset, and higher vascular risk scores predicted less change in executive function. Conclusions These results have important clinical implications, in that they suggest that a regular assessment of vascular risk in older adults with depression is necessary as a component of treatment planning and in predicting prognosis, both for the course of the depression itself and for the cognitive impairments that often accompany depression in later life.

show abstract

Section: Methodsmentioning

confidence: 99%

Cognitive Improvement Following Treatment in Late-Life Depression: Relationship to Vascular Risk and Age of Onset

Deanna

D’Angelo

Pieper

et al. 2012

The American Journal of Geriatric Psychiatry

View full text Add to dashboard Cite

show abstract

“…For 2 SRs of antidepressants [28], [29] we identified additional trials or additional data for comparisons not reported in the SR. An SR of milnacipran [28] contained no data on milnacipran versus venlafaxine: we identified a trial that reported both efficacy and safety data for this comparison. For an SR on sertraline [29] we identified an additional trial presenting previously unreported treatment-emergent adverse events for the comparison of sertraline versus reboxetine; this trial also provided additional data on withdrawals due to adverse events.…”

Section: Resultsmentioning

confidence: 99%

“…For an SR on sertraline [29] we identified an additional trial presenting previously unreported treatment-emergent adverse events for the comparison of sertraline versus reboxetine; this trial also provided additional data on withdrawals due to adverse events. Finally, we identified additional data for a comparison of adverse event rates reported in an SR on ezetimibe in hypercholesterolaemia [30].…”

Section: Resultsmentioning

confidence: 99%

Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews

et al. 2014

View full text Add to dashboard Cite

BackgroundClinical trial results registries may contain relevant unpublished information. Our main aim was to investigate the potential impact of the inclusion of reports from industry results registries on systematic reviews (SRs).MethodsWe identified a sample of 150 eligible SRs in PubMed via backward selection. Eligible SRs investigated randomized controlled trials of drugs and included at least 2 bibliographic databases (original search date: 11/2009). We checked whether results registries of manufacturers and/or industry associations had also been searched. If not, we searched these registries for additional trials not considered in the SRs, as well as for additional data on trials already considered. We reanalysed the primary outcome and harm outcomes reported in the SRs and determined whether results had changed. A “change” was defined as either a new relevant result or a change in the statistical significance of an existing result. We performed a search update in 8/2013 and identified a sample of 20 eligible SRs to determine whether mandatory results registration from 9/2008 onwards in the public trial and results registry ClinicalTrials.gov had led to its inclusion as a standard information source in SRs, and whether the inclusion rate of industry results registries had changed.Results133 of the 150 SRs (89%) in the original analysis did not search industry results registries. For 23 (17%) of these SRs we found 25 additional trials and additional data on 31 trials already included in the SRs. This additional information was found for more than twice as many SRs of drugs approved from 2000 as approved beforehand. The inclusion of the additional trials and data yielded changes in existing results or the addition of new results for 6 of the 23 SRs. Of the 20 SRs retrieved in the search update, 8 considered ClinicalTrials.gov or a meta-registry linking to ClinicalTrials.gov, and 1 considered an industry results registry.ConclusionThe inclusion of industry and public results registries as an information source in SRs is still insufficient and may result in publication and outcome reporting bias. In addition to an essential search in ClinicalTrials.gov, authors of SRs should consider searching industry results registries.

show abstract

“…The dose was selected to lessen potential adverse effects as well as for ease of administration [65, 67]. For the purposes of the trial, sertraline tablets will be encapsulated and microcrystalline cellulose will be added to the capsule to prevent the tablet from rattling within.…”

Section: Methodsmentioning

confidence: 99%

“…Due to the lack of anti-cholinergic effects as well as few interactions with other medications, sertraline is more tolerable than alternate classes of antidepressant [65]. A number of reviews suggest that sertraline is the most suitable first choice of antidepressant in patients suffering major depression due to its balance of efficacy and acceptability [67]. …”

Section: Introductionmentioning

confidence: 99%

The Beyond Ageing Project Phase 2 - a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial

Cockayne

Duffy

Bonomally

et al. 2015

Trials

View full text Add to dashboard Cite

BackgroundLate-life depression is associated with high rates of morbidity, premature mortality, disability, functional decline, caregiver burden and increased health care costs. While clinical and public health approaches are focused on prevention or early intervention strategies, the ideal method of intervention remains unclear. No study has set out to evaluate the role of neurobiological agents in preventing depressive symptoms in older populations at risk of depression.Methods/DesignSubjects with previously reported sub-threshold depressive symptoms, aged 60 to 74 years, will be screened to participate in a single-centre, double-blind, randomised controlled trial with three parallel groups involving omega-3 fatty acid supplementation or sertraline hydrochloride, compared with matching placebo. Subjects will be excluded if they have current depression or suicide ideation; are taking antidepressants or any supplement containing omega-3 fatty acid; or have a prior history of stroke or other serious cerebrovascular or cardiovascular disease, neurological disease, significant psychiatric disease (other than depression) or neurodegenerative disease. The trial will consist of a 12 month treatment phase with follow-up at three months and 12 months to assess outcome events. At three months, subjects will undergo structural neuroimaging to assess whether treatment effects on depressive symptoms correlate with brain changes. Additionally, proton spectroscopy techniques will be used to capture brain-imaging markers of the biological effects of the interventions. The trial will be conducted in urban New South Wales, Australia, and will recruit a community-based sample of 450 adults. Using intention-to-treat methods, the primary endpoint is an absence of clinically relevant depression scores at 12 months between the omega-3 fatty acid and sertraline interventions and the placebo condition.DiscussionThe current health, social and economic costs of late-life depression make prevention imperative from a public health perspective. This innovative trial aims to address the long-neglected area of prevention of depression in older adults. The interventions are targeted to the pathophysiology of disease, and regardless of the effect size of treatment, the outcomes will offer major scientific advances regarding the neurobiological action of these agents. The main results are expected to be available in 2017.Trial RegistrationAustralian and New Zealand Clinical Trials Registry ACTRN12610000032055 (12 January 2010)Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-015-0762-6) contains supplementary material, which is available to authorized users.

show abstract

Sertraline versus other antidepressive agents for depression

Cited by 87 publications

References 97 publications

Cognitive Improvement Following Treatment in Late-Life Depression: Relationship to Vascular Risk and Age of Onset

Cognitive Improvement Following Treatment in Late-Life Depression: Relationship to Vascular Risk and Age of Onset

Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews

The Beyond Ageing Project Phase 2 - a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About